A Study of sEphB4-HSA in Kaposi Sarcoma

Status Recruiting

Clinical Trial Summary

sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.

Clinical Trial Description

sEphB4-HSA will be given through an intravenous infusion (into a vein). Each cycle of sEphB4-HSA will be 28 days (4 weeks). Each cycle of the study drug includes administration of 2 doses of sEphB4-HSA given on Days 1 and 15 of each cycle. Participants may continue on study protocol as long as their KS is continuing to respond or is clinically stable on study medication. Patients may come off treatment for the following reasons: - Disease progression. - Need for more than 2 dose reductions for toxicity. - Dose delay more than 28 days. - Patient withdraws consent. - Study termination by the Sponsor. - Participants who are noncompliant with respect to taking drugs, keeping appointments, or having tests required for the evaluation of drug safety and efficacy. - Participant's condition renders them unacceptable for further treatment in the judgment of the investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03993106
Study type	Interventional
Source	Vasgene Therapeutics, Inc
Contact	Sarah E. Cole, M.S.
Phone	626-840-7756
Email	scoleemail@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	September 17, 2020
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04941274` - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	Phase 1/Phase 2
Completed	`NCT03160183` - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting	`NCT05081141` - HHV8 and Solid Organ Transplantation
Completed	`NCT00395278` - Development of Serologic Assays for Human Herpes Virus-8
Recruiting	`NCT02408861` - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Completed	`NCT03296553` - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.	Phase 2
Recruiting	`NCT04305691` - Trial of Ixazomib for Kaposi Sarcoma	Phase 2
Completed	`NCT03316274` - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma	Early Phase 1
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Terminated	`NCT04893018` - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV	Phase 1
Recruiting	`NCT05663502` - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Not yet recruiting	`NCT06375122` - Natural History Study of Kaposi Sarcoma
Recruiting	`NCT05329792` - L19IL2/L19TNF in Skin Cancer Patients	Phase 2
Not yet recruiting	`NCT05411237` - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma	Phase 3
Completed	`NCT03050788` - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma	N/A
Completed	`NCT03404297` - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya	N/A
Terminated	`NCT01412515` - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma	Phase 2
Not yet recruiting	`NCT06004011` - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)	N/A
Withdrawn	`NCT02229981` - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	Phase 1/Phase 2
Terminated	`NCT02080416` - Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors	Phase 0